作者
Robert H Knopp, Christine Tsunehara, Barbara M Retzlaff, Brian Fish, Hien Nguyen, Susan Anderson, Thuy Nguyen
发表日期
2006/12/1
期刊
Metabolism
卷号
55
期号
12
页码范围
1697-1703
出版商
WB Saunders
简介
Two drug classes act in the intestine to lower cholesterol. Ezetimibe inhibits cholesterol absorption, whereas bile acid–binding resins enhance cholesterol excretion via enhanced conversion to bile acids. Combining these 2 classes may be beneficial, but cholestyramine binds ezetimibe, and the combined effect of colesevelam hydrochloride and ezetimibe was little studied. The aim of the study was to determine if adding colesevelam HCl to ezetimibe provides additional lowering of low-density lipoprotein– and apolipoprotein B–containing lipoproteins or alters ezetimibe levels. Twenty subjects with low-density lipoprotein cholesterol (LDL-C) levels of 130 mg/dL or higher were enrolled and taught a National Cholesterol Education Program Step I diet. At a second baseline visit, lipoproteins were measured and subjects were randomly allocated to (1) ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E …
引用总数
20072008200920102011201220132014201520162017201820192020202120224459553211111